Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Survival and prognostic factors of early-stage non-small cell lung cancer in Central and Eastern Europe: A prospective cohort study

M. Sheikh, S. Virani, HA. Robbins, L. Foretova, I. Holcatova, V. Janout, J. Lissowska, M. Navratilova, A. Mukeriya, M. Ognjanovic, B. Swiatkowska, D. Zaridze, P. Brennan

. 2023 ; 12 (9) : 10563-10574. [pub] 20230323

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011558

BACKGROUND: Although early diagnosis and surgical resection of the tumor have been shown to be the most important predictors of lung cancer survival, long-term survival for surgically-resected early-stage lung cancer remains poor. AIMS: In this prospective study we aimed to investigate the survival and prognostic factors of surgically-resected early-stage non-small cell lung cancer (NSCLC) in Central and Eastern Europe. METHODS: We recruited 2052 patients with stage I-IIIA NSCLC from 9 centers in Russia, Poland, Serbia, Czech Republic, and Romania, between 2007-2016 and followed them annually through 2020. RESULTS: During follow-up, there were 1121 deaths (including 730 cancer-specific deaths). Median survival time was 4.9 years, and the 5-year overall survival was 49.5%. In the multivariable model, mortality was increased among older individuals (HR for each 10-year increase: 1.31 [95% CI: 1.21-1.42]), males (HR:1.24 [1.04-1.49]), participants with significant weight loss (HR:1.25 [1.03-1.52]), current smokers (HR:1.30 [1.04-1.62]), alcohol drinkers (HR:1.22 [1.03-1.44]), and those with higher stage tumors (HR stage IIIA vs. I: 5.54 [4.10 - 7.48]). However, education, chronic obstructive pulmonary diseases (COPD), and tumor histology were not associated with risk of death. All baseline indicators of smoking and alcohol drinking showed a dose-dependent association with the risk of cancer-specific mortality. This included pack-years of cigarettes smoked (p-trend = 0.04), quantity of smoking (p-trend = 0.008), years of smoking (p-trend = 0.010), gram-days of alcohol drank (p-trend = 0.002), frequency of drinking (p-trend = 0.006), and years of drinking (p-trend = 0.016). CONCLUSION: This study shows that the 5-year survival rate of surgically-resected stage I-IIIA NSCLC is still around 50% in Central and Eastern Europe. In addition to non-modifiable prognostic factors, lifetime patterns of smoking and alcohol drinking affected the risk of death and disease progression in a dose-dependent manner in this population.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011558
003      
CZ-PrNML
005      
20230801133134.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.5791 $2 doi
035    __
$a (PubMed)36952375
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sheikh, Mahdi $u Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France $1 https://orcid.org/0000000339727824
245    10
$a Survival and prognostic factors of early-stage non-small cell lung cancer in Central and Eastern Europe: A prospective cohort study / $c M. Sheikh, S. Virani, HA. Robbins, L. Foretova, I. Holcatova, V. Janout, J. Lissowska, M. Navratilova, A. Mukeriya, M. Ognjanovic, B. Swiatkowska, D. Zaridze, P. Brennan
520    9_
$a BACKGROUND: Although early diagnosis and surgical resection of the tumor have been shown to be the most important predictors of lung cancer survival, long-term survival for surgically-resected early-stage lung cancer remains poor. AIMS: In this prospective study we aimed to investigate the survival and prognostic factors of surgically-resected early-stage non-small cell lung cancer (NSCLC) in Central and Eastern Europe. METHODS: We recruited 2052 patients with stage I-IIIA NSCLC from 9 centers in Russia, Poland, Serbia, Czech Republic, and Romania, between 2007-2016 and followed them annually through 2020. RESULTS: During follow-up, there were 1121 deaths (including 730 cancer-specific deaths). Median survival time was 4.9 years, and the 5-year overall survival was 49.5%. In the multivariable model, mortality was increased among older individuals (HR for each 10-year increase: 1.31 [95% CI: 1.21-1.42]), males (HR:1.24 [1.04-1.49]), participants with significant weight loss (HR:1.25 [1.03-1.52]), current smokers (HR:1.30 [1.04-1.62]), alcohol drinkers (HR:1.22 [1.03-1.44]), and those with higher stage tumors (HR stage IIIA vs. I: 5.54 [4.10 - 7.48]). However, education, chronic obstructive pulmonary diseases (COPD), and tumor histology were not associated with risk of death. All baseline indicators of smoking and alcohol drinking showed a dose-dependent association with the risk of cancer-specific mortality. This included pack-years of cigarettes smoked (p-trend = 0.04), quantity of smoking (p-trend = 0.008), years of smoking (p-trend = 0.010), gram-days of alcohol drank (p-trend = 0.002), frequency of drinking (p-trend = 0.006), and years of drinking (p-trend = 0.016). CONCLUSION: This study shows that the 5-year survival rate of surgically-resected stage I-IIIA NSCLC is still around 50% in Central and Eastern Europe. In addition to non-modifiable prognostic factors, lifetime patterns of smoking and alcohol drinking affected the risk of death and disease progression in a dose-dependent manner in this population.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a nemalobuněčný karcinom plic $x epidemiologie $x chirurgie $7 D002289
650    12
$a nádory plic $x epidemiologie $x chirurgie $7 D008175
650    _2
$a prospektivní studie $7 D011446
650    _2
$a prognóza $7 D011379
650    12
$a malobuněčný karcinom plic $x patologie $7 D055752
650    _2
$a staging nádorů $7 D009367
651    _2
$a Polsko $7 D011044
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Virani, Shama $u Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France $1 https://orcid.org/000000021163432X
700    1_
$a Robbins, Hilary A $u Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France $1 https://orcid.org/0000000160416866
700    1_
$a Foretova, Lenka $u Department of Cancer Epidemiology & Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic $1 https://orcid.org/0000000304942620
700    1_
$a Holcatova, Ivana $u Department of Public Health and Preventive Medicine, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Oncology, 2nd Medical Faculty & University Hospital Motol, Prague, Czech Republic
700    1_
$a Janout, Vladimir $u Faculty of Medicine, Palacky University, Olomouc, Czech Republic
700    1_
$a Lissowska, Jolanta $u Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland $1 https://orcid.org/0000000326955799
700    1_
$a Navratilova, Marie $u Department of Cancer Epidemiology & Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Mukeriya, Anush $u Department of Clinical Epidemiology, N.N. Blokhin National Medical Research Centre of Oncology, Moscow, Russia
700    1_
$a Ognjanovic, Miodrag $u International Organization for Cancer Prevention and Research, Belgrade, Serbia
700    1_
$a Swiatkowska, Beata $u Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Poland
700    1_
$a Zaridze, David $u Department of Clinical Epidemiology, N.N. Blokhin National Medical Research Centre of Oncology, Moscow, Russia $1 https://orcid.org/0000000228243704
700    1_
$a Brennan, Paul $u Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France $1 https://orcid.org/0000000205188714
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 12, č. 9 (2023), s. 10563-10574
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36952375 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133131 $b ABA008
999    __
$a ok $b bmc $g 1963778 $s 1197823
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 12 $c 9 $d 10563-10574 $e 20230323 $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
LZP    __
$a Pubmed-20230718
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace